Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel-Klotho Protein Therapy
Innovative Modified Soluble α-Klotho Protein Shows Promise for Treating the $16B Chronic Kidney Disease and Phosphate Metabolism Disorders Markets
United States, 14th Oct 2025 – Anzor Pharmaceuticals is pleased to announce the issuance of U.S. Patent No. 12,227,777 B2 for a novel modified soluble α-Klotho protein with enhanced therapeutic properties. This breakthrough technology represents a significant advancement in the treatment of chronic kidney disease (CKD) and conditions associated with disrupted fibroblast growth factor 23 (FGF23) signaling.
Revolutionary Approach to FGF23 Signaling
The patented technology centers on a modified soluble α-Klotho protein engineered to substantially reduce binding affinity for certain FGF receptors while maintaining its critical co-receptor function for FGF23. This precision-engineered protein addresses a fundamental challenge in treating phosphate metabolism disorders and kidney disease.
“This patent represents years of dedicated research into understanding the complex molecular mechanisms of α-Klotho and FGF23 signaling,” said Dr. Moosa Mohammadi, Chief Scientific Officer, Anzor Pharmaceuticals. “Our modified α-Klotho protein acts as an on-demand co-receptor for FGF23, offering a more targeted therapeutic approach than current treatments.”
Key Therapeutic Applications
The modified α-Klotho protein shows promise for treating multiple conditions, including:
• Chronic Kidney Disease (CKD) and associated complications
• Hypophosphatemic conditions, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemic rickets (XLH), and tumor-induced osteomalacia (TIO)
• Renal phosphate wasting disorders
• Cardiovascular complications associated with kidney disease, including left ventricular hypertrophy
Scientific Innovation
The technology disclosed in the patent demonstrates several key advantages:
• Enhanced specificity for FGF23-FGFR signaling pathways
• Reduced off-target effects compared to wildtype α-Klotho
• Ability to function as a precision co-receptor, promoting targeted FGF23-FGFRIc proximity
• Crystallographically-validated molecular structure confirming enhanced binding properties
• Demonstrated efficacy in preclinical models for reducing serum phosphate and increasing renal phosphate excretion
According to the patent data, the modified protein successfully forms a 1:1:1 FGF23-FGFRIc-αKlotho ternary complex that enables precise control over FGF23 signaling, a critical pathway in mineral homeostasis.
About α-Klotho and FGF23 α-Klotho is an essential protein that functions as a co-receptor for FGF23, playing a crucial role in regulating phosphate and vitamin D homeostasis. Disruption of FGF23 signaling contributes to various pathological conditions, particularly in patients with chronic kidney disease. The novel modified α-Klotho protein developed by Anzor Pharmaceuticals is designed to restore proper FGF23 signaling in these patients.
Next Steps
Anzor Pharmaceuticals is currently advancing this technology through preclinical development with plans to initiate clinical trials. The company is also exploring additional therapeutic applications of the modified α-Klotho platform technology. “This patent strengthens our intellectual property portfolio and validates our scientific approach,” added Chris Adams, Chief Executive Officer of Anzor Pharmaceuticals. “We believe this technology has the potential to address significant unmet medical needs in patients suffering from kidney disease and phosphate metabolism disorders.”
About Anzor Pharmaceuticals
Anzor Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative protein therapeutics for metabolic and kidney diseases. The company’s research focuses on addressing critical gaps in treatment options for patients with rare and chronic conditions affecting phosphate homeostasis and renal function.
For more information about Anzor Pharmaceuticals and its pipeline, please visit [www.anzorpharma.com].
Company Details
Organization: Anzor Pharmaceuticals
Contact Person: Christopher Adams
Website: https://anzorpharma.com
Email: Send Email
Contact Number: +16179579858
Country: United States
Release Id: 14102535326